Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 7/20 | 0.66 |
| ▸ | WNT3A | P56704 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831672 | 0.89 | ATM (0.72) | CTNNB1WNT3AALDH1A1MAPK1HPGD | |
| SCHEMBL2237626 | 0.87 | MEN1 (0.76) | CTNNB1WNT3AALDH1A1MAPK1MEN1 | |
| SCHEMBL29458253 | 0.87 | MEN1 (0.76) | CTNNB1WNT3AALDH1A1MAPK1MEN1 | |
| SCHEMBL10961709 | 0.86 | CTNNB1 (0.71) | CTNNB1WNT3AALDH1A1MAPK1MEN1 | |
| SCHEMBL6486626 | 0.85 | CTNNB1 (0.66) | CTNNB1WNT3AALDH1A1MAPK1MEN1 | |
| SCHEMBL7253369 | 0.84 | CTNNB1 (0.64) | CTNNB1WNT3AALDH1A1MAPK1MEN1 | |
| SCHEMBL1092123 | 0.84 | ATM (0.81) | CTNNB1WNT3AALDH1A1MAPK1MEN1 | |
| SCHEMBL4258312 | 0.84 | CTNNB1 (0.64) | CTNNB1WNT3AALDH1A1MAPK1MEN1 | |
| SCHEMBL2843731 | 0.84 | CTNNB1 (0.64) | CTNNB1WNT3AALDH1A1MAPK1MEN1 | |
| SCHEMBL13785040 | 0.84 | CTNNB1 (0.64) | CTNNB1WNT3AALDH1A1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456187-B2 | Furanopyrimidine compounds as potassium ion channel inhibitors | XENTION LIMITED (GB) | 2008-11-25 | — | — | US | disclosed |
| EP-1758909-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121149-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| US-20050282829-A1 | Furanopyrimidine compounds as potassium ion channel inhibitors | XENTION DISCOVERY LTD. (GB) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282829-A1 | Furanopyrimidine compounds as potassium ion channel inhibitors | KCNH3, HCN4, KCNH2 | CTNNB1 2579/4885WNT3A 3475/4885ALDH1A1 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.